Pathogen inactivated platelets and prevention of immunological adverse reactions: The Italian platelet technology assessment study (IPTAS)

Blood Transfusion

Volumn 7, Issue SUPPL. 1, 2009, Pages

  Rebulla, P ^a   Grazzini, G ^a   Liumbruno, G M ^a   Aprili, G ^a   Formisano, S ^a   Girelli, G ^a   Marconi, M ^a   Salvaneschi, L ^a   Strada, P ^a   Zolla, L ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; BLOOD COMPONENT; BLOOD TRANSFUSION REACTION; CLINICAL ASSESSMENT; CONFERENCE PAPER; COST BENEFIT ANALYSIS; HLA MATCHING; HUMAN; INCIDENCE; ITALY; LEUKOCYTE; OUTCOME ASSESSMENT; PATHOGENESIS; POPULATION; PROTEIN MODIFICATION; PROTEOMICS; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SAMPLE SIZE; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION;

EID: 60749092477     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0013-09     Document Type: Conference Paper

References (19)

1. van Rhenen D, Gulliksson H, Cazenave JP, et al; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
2. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-41.
3. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004; 44: 1732-40.
4. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
5. Janetzko K, Cazenave JP, Klüter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45: 1443-52.
6. Goodrich RP, Li J, Pieters H, et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-85.
7. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46: 731-40.
8. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22: 1-34.
9. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-82.
10. Mowatt G, Bower DJ, Brebner JA, et al. When is the "right" time to initiate an assessment of a health technology. Int J Tech Assess Health Care 1998; 14: 372-86.
11. Wurtz V, Hechler B, Ohlmann P, et al. Identification of platelet factor 4 and beta-thromboglobulin by profiling and liquid chromatography tandem mass spectrometry of supernatant peptides in stored apheresis and buffy-coat platelet concentrates. Transfusion 2007; 47: 1099-101.
12. Thiele T, Steil L, Völker U, Greinacher A. Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine. BioDrugs. 2007; 21: 179-93.
13. Thiele T, Steil L, Gebhard S, et al. Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion 2007; 47: 1221-33.
14. Glenister KM, Payne KA, Sparrow RL. Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage. Transfusion 2008; 48: 99-107.
15. Schiffer CA, Anderson KC, Bennett CL, et al.; American Society of Clinical Oncology. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.
16. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997 Dec 25; 337 (26): 1861-9.
17. Feinstein AR. Principles of medical statistics. Boca Raton, FL; CRC, 2002:503.
18. D'Amici GM, Rinalducci S, Zolla L. Proteomic analysis of RBC membrane protein degradation during blood storage. J Proteome Res 2007; 6: 3242-55.
19. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996; 68: 850-8.